Login to Your Account

Heptares, AstraZeneca GPCR Deal Worth Potential $186M

By Nuala Moran

Wednesday, June 1, 2011
LONDON – Heptares Ltd. announced a four-year collaboration with AstraZeneca plc worth a potential $186 million, plus funding for research and development. That is the third deal this year around Heptares' stabilized G-protein coupled receptor (GPCR) platform and the first in which the technology will be used for antibody discovery. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription